Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial

Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial
Treatment with Abivax's ABX464 showed continuing effectiveness in ulcerative colitis patients, according to nine-month data of a maintenance clinical trial. The company is now recruiting people with moderate-to-severe ulcerative colitis for its Phase 2b trial (NCT03760003) of ABX464, to be conducted in up to 150 sites in more than 15 countries. ABX464 is a small molecule taken once daily by mouth. It works by targeting a group of proteins called the Cap Binding Complex, a novel mechanism of action for anti-inflammatory therapies. This leads to a series of events within cells, namely the production of microRNA-124 (miR-124). This molecule reduces the production of inflammatory signals, thus "putting the brakes" on inflammation. The treatment was tested in a Phase 2a clinical trial (NCT03093259) in which 32 participants were randomly selected to receive either 50 milligrams of ABX464 or a placebo for eight weeks. A total 29 patients completed the trial, and 35% of those given ABX464 were in clinical remission at the study's end. After this study, all participants had the option to continue in an open-label extension of the study — that is, a continuation in which all patients are given the treatment, without placebos — called ABX464-102 (NCT03368118). At the Digestive Disease Week (DDW) 2019 conference, held recently in San Diego, data was presented for 19 patients. The seven who were in clinical remission at the end of the the trial remained in that status through the nine months of the extension study. Among the 12 patients not in clinical remission at the end of the initial study, 11 were reported to have "at least a clinical response" by the end of the extension study. None of the 12 were reported to be in remission by the extension study's concl
Subscribe or to access all post and page content.